论文部分内容阅读
应用同时推量加速调强放疗技术 (SIB- IMART)治疗 15例头颈部恶性肿瘤 ,肉眼靶区 (GTV)的平均剂量为 70 Gy,临床靶区 (CTV)的平均剂量为 5 4 Gy,脑干、脊髓及腮腺等正常组织的受量均在允许范围之内。结果13例 38天内完成治疗 ,2例因副作用而中断放疗 ;皮肤反应 级 12例、 级 3例 ;粘膜反应 级 9例、 级 4例、 级 2例 ,咽部及食管 级 10例、 级 3例、 级 2例 ;唾液腺副作用明显较传统放疗技术轻 ,15例中 0级 3例、 级 10例、 级 2例 ;口干 0级 3例、 级 9例、 级 3例 ,无重度或完全口干病例。放疗结束后疗效达 CR者 13例 ,PR者 2例 ,无一例出现病情进展。认为 SIB- IMART治疗头颈部恶性肿瘤安全可行 ,特别是腮腺可受到较好保护 ,且不同的靶区可以同时实现不同的剂量水平 ,缩短了治疗时间
Fifteen cases of head and neck malignancies were treated with SIB-IMART. The average dose of GTV was 70 Gy and the average dose of CTV was 54 Gy. The brain Dry, spinal cord and parotid gland and other normal tissues by the amount are within the allowable range. Results Thirteen cases were cured within 38 days and two cases were interrupted due to side effects. There were 12 cases of skin reaction and 3 cases of grade. There were 9 cases of mucosal reaction, 4 cases of grade, 2 cases of grade, 10 cases of pharynx and esophagus, Cases of grade 2 cases; salivary gland side effects were significantly less than the traditional radiotherapy techniques, 15 cases 0 in 3 cases, 10 cases in grade, 2 cases; dry mouth 0 3 cases, 9 cases in grade, 3 cases without severe or complete Dry mouth cases. Radiotherapy after CR effect in 13 cases, PR in 2 cases, no case of disease progression. It is considered that SIB-IMART is safe and feasible for the treatment of head and neck malignant tumors, especially the parotid gland can be well protected, and different target areas can simultaneously achieve different dose levels and shorten the treatment time